Clin2
NCT06640582Possibly a fitRecruiting

TIL therapy with pembrolizumab for advanced brain cancer

Brain TumorBrain MetastasesBrain CancerGliomaGliomas, MalignantGlioblastomaMeningioma

Treatments studied

Part of Brain & nervous system, Cancer clinical trials.

This trial tests a new treatment for advanced brain cancers like glioma and meningioma. It combines your own immune cells (tumor-infiltrating lymphocytes or TILs) with an immunotherapy drug (pembrolizumab) to help your body fight the tumor. It's for people who have tried other treatments without success or have no standard options left.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
85 people
Ages
16 years to 90 years
Study type
Interventional

Who can take part

  • You are 16 to 90 years old.
  • You have a type of brain cancer called glioma or meningioma that has come back, spread, or not responded to treatment.
  • You are healthy enough for surgery to remove a tumor sample, and your expected survival is more than 3 months.
  • You can perform daily activities with some help (Karnofsky score 60% or higher, or ECOG 0-2).
  • Your blood counts and organ function are within certain limits (checked within the week before starting).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04943913Recruiting· Early Phase 1
TIL cell therapy for brain glioma after standard treatment fails

This early-stage study tests a treatment made from your tumor’s immune cells (TILs) to help shrink brain glioma. You may be considered if your glioma is back or has spread and standard options are no longer working (or don’t exist).

Suzhou, Jiangsu
NCT06532799Recruiting· Phase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer

This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.

Beijing, Beijing Municipality
NCT06532812Recruiting· Phase 1/Phase 2
TIL therapy plus immunotherapy for advanced breast cancer

This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.

Beijing, Beijing Municipality
NCT06538012Recruiting· Phase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer

This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.

Beijing, Beijing Municipality
NCT05087745Recruiting· Early Phase 1
TIL therapy for advanced solid tumors

This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.

Hangzhou, Zhejiang
NCT04967833Recruiting· Early Phase 1
Testing TIL cell therapy for advanced solid tumors

This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.

Shanghai

Hear when a new Brain Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.